{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:54:07Z","timestamp":1781067247248,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine\/naloxone induction.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine\/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a buprenorphine\/naloxone microdosing schedule, we initiated treatment of an individual\u2019s opioid use disorder. There was a successful buprenorphine\/naloxone microdosing induction as the team reached a therapeutic dose of buprenorphine\/naloxone. Including the induction period, the medication was used consistently for 4\u00a0weeks.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A microdosing schedule can be used to induce a patient onto buprenorphine\/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine\/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13722-020-0177-x","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T14:02:52Z","timestamp":1579096972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Case report: Successful induction of buprenorphine\/naloxone using a microdosing schedule and assertive outreach"],"prefix":"10.1186","volume":"15","author":[{"given":"Jennifer","family":"Rozylo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-3923","authenticated-orcid":false,"given":"Mohammadali","family":"Nikoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Elise","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye P.","family":"Barbic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"177_CR1","unstructured":"British Columbia Coroners Service. Illicit drug overdose deaths in BC January 1, 2008\u2013January 31, 2018; 2018."},{"key":"177_CR2","unstructured":"Global Commission on Drug Policy. The opioid crisis in North America; 2017."},{"key":"177_CR3","unstructured":"Government of Canada. Deaths [Internet]. https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/990513\/dq990513a-eng.htm. Accessed 1 Dec 2019."},{"key":"177_CR4","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in (released September 2018)\u2014Canada.ca. Ottawa; 2018."},{"key":"177_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"177_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. https:\/\/doi.org\/10.1002\/14651858.CD002209.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"177_CR7","first-page":"CD004145","volume":"8","author":"L Gowing","year":"2011","unstructured":"Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane database Syst Rev. 2011;8:CD004145.","journal-title":"Cochrane database Syst Rev"},{"key":"177_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2015.08.037","volume":"156","author":"S Nolan","year":"2015","unstructured":"Nolan S, Hayashi K, Milloy MJ, Kerr T, Dong H, Lima VD, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015;156:57\u201361.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"177_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"Y-I Hser","year":"2016","unstructured":"Hser Y-I, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695\u2013705.","journal-title":"Addiction"},{"issue":"1\u20133","key":"177_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1\u20133):151\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"177_CR11","unstructured":"British Columbia Center on Substance Use. A guideline for the clinical management of opioid use disorder; 2017."},{"key":"177_CR12","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M\u00c8, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190:E247\u201357.","journal-title":"CMAJ"},{"key":"177_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ajad.12213","volume":"24","author":"R Daniulaityte","year":"2015","unstructured":"Daniulaityte R, Carlson R, Brigham G, Cameron D, Sheth A. Sub is a weird drug: a web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms. Am J Addict. 2015;24:403\u20139.","journal-title":"Am J Addict"},{"key":"177_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/02791072.2014.921743","volume":"46","author":"C Teruya","year":"2014","unstructured":"Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine\/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46:412\u201326.","journal-title":"J Psychoactive Drugs"},{"key":"177_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13722-019-0146-4","volume":"14","author":"A Srivastava","year":"2019","unstructured":"Srivastava A, Kahan M, Leece P, McAndrew A. Buprenorphine unobserved \u201chome\u201d induction: a survey of Ontario\u2019s addiction physicians. Addict Sci Clin Pract. 2019;14:18.","journal-title":"Addict Sci Clin Pract"},{"key":"177_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1055\/s-0030-1261914","volume":"11","author":"R Ha\u0308mmig","year":"2010","unstructured":"Ha\u0308mmig R. Einleitung einer Substitutionsbehandlung mit Buprenorphin unter voru\u0308bergehender U\u0308berlappung mit Heroinkonsum: ein neuer Ansatz (\u201cBerner Methode\u201d) [Induction of a buprenorphine substitution treatment with temporary overlap of heroin use: a new approach (\u201cBernese Method\u201d)]. Suchttherapie. 2010;11:129\u201332 (in German).","journal-title":"Suchttherapie"},{"key":"177_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R Hammig","year":"2016","unstructured":"Hammig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105.","journal-title":"Subst Abuse Rehabil"},{"key":"177_CR18","unstructured":"Government of British Columbia. Overdose prevention and response in B.C. [Internet]; 2019. https:\/\/www.stopoverdose.gov.bc.ca\/. Accessed 9 Feb 2019."},{"issue":"1","key":"177_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/24740527.2019.1599279","volume":"3","author":"R Sandhu","year":"2019","unstructured":"Sandhu R, Zivanovic R, Klaire S, Nikoo M, Rozylo J, Azar P. Buprenorphine\/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: a case report. Can J Pain. 2019;3(1):79\u201384. https:\/\/doi.org\/10.1080\/24740527.2019.1599279.","journal-title":"Can J Pain"},{"key":"177_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/wps.20234","volume":"14","author":"GR Bond","year":"2015","unstructured":"Bond GR, Drake RE. The critical ingredients of assertive community treatment. World Psychiatry. 2015;14:240\u20132.","journal-title":"World Psychiatry"},{"issue":"6","key":"177_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/15332985.2017.1302038","volume":"15","author":"DJ Hurley","year":"2017","unstructured":"Hurley DJ, O\u2019Reilly RL. Resilience, mental health and assertive community treatment. Soc Work Ment Health. 2017;15(6):730\u201348. https:\/\/doi.org\/10.1080\/15332985.2017.1302038.","journal-title":"Soc Work Ment Health"},{"issue":"3","key":"177_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamapsychiatry.2017.4432","volume":"75","author":"AA Jones","year":"2018","unstructured":"Jones AA, Jang K, Panenka WJ, Barr AM, MacEwan GW, Thornton AE, et al. Rapid change in fentanyl prevalence in a community-based high-risk sample. JAMA Psychiatry. 2018;75(3):298\u2013300.","journal-title":"JAMA Psychiatry"},{"key":"177_CR23","unstructured":"Department of Justice Canada. Methamphetamine report for federal-provintial-terriorial ministers responsible for justice. [Internet]; 2007. https:\/\/www.justice.gc.ca\/eng\/rp-pr\/other-autre\/meth\/p3.html. Accessed 9 Feb 2019."},{"key":"177_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","volume":"104","author":"J Bell","year":"2009","unstructured":"Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193\u2013200.","journal-title":"Addiction"},{"key":"177_CR25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","volume":"20","author":"MD Stein","year":"2005","unstructured":"Stein MD, Cloe P, Friedmann PD. Brief report: buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038\u201341.","journal-title":"J Gen Intern Med"},{"key":"177_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","volume":"98","author":"RP Mattick","year":"2003","unstructured":"Mattick RP, Ali R, White JM, O\u2019Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441\u201352.","journal-title":"Addiction"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-020-0177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13722-020-0177-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-020-0177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:13:14Z","timestamp":1610583194000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-020-0177-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1186\/s13722-020-0177-x","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from participant. As per communication with the research board, ethics approval was not required for the case reports.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No personal identifier is included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no potential conflicts of interest. The authors alone are responsible for the content and writing of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}